The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...

Aortic valve stenosis (AVS) is a significant health concern ... Researchers at Mayo Clinic are exploring the use of a new drug called ataciguat to manage AVS. In AVS, calcium deposits build ...

Fibrosis predicts post-surgical risk in aortic stenosis, reinforcing its role in guiding treatment decisions for both sexes.

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...